Dr. Harish Hosalkar, conducted his medical school training and initial orthopedic residency at the University of Mumbai where he was the recipient of several gold medals and awards including the prestigious ‘President of India Gold Medal’ and stood first at University of Mumbai for the final MBBS examination. He then completed his specialized orthopedic training in the United Kingdom and then in the United States.
He currently serves as President of Orthopedic Rehabilitation Association (subspecialty society of AAOS) & SAPI (San Diego Association of Physicians of Indian Origin) while being in active practice in six hospitals in San Diego and multiple surgery centers. At the ‘San Diego Spine & Joint Center’ within Paradise Valley Hospital, Dr. Hosalkar serves as the Director of Joint Preservation and Deformity Correction catering to the entire age-spectrum including teenagers, young adults and older patients. He is also the medical Director of the Center for Hip Preservation and Children’s Orthopedics in Vista, Carmel Mountain and Sorrento Valley, CA. He practices within the Scripps Hospital system, Sharp Hospital system, Tricity Medical Center and Prime Health system.
Dr. Hosalkar is the recipient of several awards including the ‘William Bora Award’, ‘DeForrest Willard Best Senior Resident Award’ and the ‘Stanley Chung Research Award’ during his orthopedic residency at University of Pennsylvania. He is a board certified orthopedic surgeon and holds active medical licensure to practice in multiple states in United States, and in India & United Kingdom. He is fellowship trained in traumatology, deformity correction, neuro-muscular orthopedics, joint preservation and reconstruction (Berne, Switzerland), and in children’s orthopedics.
To know more about Dr Hosalkar please visit www.drhosalkar.com
Scott M. Lippman, MD, the Director of the UCSD Moore’s Cancer Center, brings more than 25 years of experience as principal investigator of translational research involving investigator-initiated clinical trials and maintains an active clinical practice. As a clinician, he is well-respected by his peers, with recognition in every major “Top Doctor” listing including U.S. News & World Report. His research interests include clinical and translational research focused on head and neck and lung cancer; genetic drivers of cancer; predictive molecular signatures, biomarkers for clinical response in solid tumors; design of trials using molecular targets and markers for cancer prevention and therapy. Since 1990, he has had continuous funding from the National Cancer Institute (NCI), including as principal investigator of major programmatic grants to develop personalized or precision medicine. He received The University of Texas MD Anderson Cancer Center team science award for his leadership of the multidisciplinary molecular-guided Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial for lung cancer.
Dr. Steinhubl, MD. is the Director of Digital Medicine at STSI and a cardiologist at Scripps Health, Scripps Clinic. He received his undergraduate training in chemical engineering at Purdue University in Indiana, graduate training in physiology at Georgetown University in Washington, DC, and his medical degree at St. Louis University in Missouri. Steve’s internal medicine residency training was completed at David Grant Medical Center at Travis Air Force Base, California. Following residency, he was a staff internist at Elmendorf Air Force Base Hospital in Anchorage, Alaska. His cardiology and interventional cardiology fellowships were at the Cleveland Clinic Foundation where he was also Chief Cardiology Fellow.
Prior to joining Scripps, Steve was the Director of Cardiovascular Wellness and the Medical Director for Employee Wellness for the Geisinger Healthcare System. He was also the Cardiology Fellowship Director, a clinician-scientist and a staff cardiologist there. In the past, beyond his time in the Air Force, Steve has also been a Global Medical Vice-President for The Medicines Company based in Zurich Switzerland and the Director of Cardiovascular Education and Clinical Research at the University of Kentucky in Lexington. Dr Steinhubl’s research activities have covered a broad range of topics in cardiology with a primary early focus on trials of novel antithrombotic therapies for the treatment and prevention of cardiovascular disease, and more recently on the application of an integrated systems-based approach to the optimal identification, communication and treatment of an individual’s risk for various manifestations of cardiovascular disease. He has been principal investigator or helped lead over a dozen large-scale, international randomized trials and has authored nearly 200 peer-reviewed manuscripts as well as numerous book chapters, and abstracts.
Jon Zifferblatt, MD/MPH. Jon’s passion for the science, art, and business of healthcare has guided him through a variety of roles and experiences within the medical and healthcare industries. He is currently a member of Janssen Healthcare Innovation (JHI), a team focused on integrated care/population health business models and enabling technologies that empower patients and provide high-quality, cost effective care. Previously, Jon was a Managing Director and co-owner of GBI Health,a health care data firm based in Shanghai, where he also co-chaired the healthcare committee of the American Chamber of Commerce. He has worked in executive, research, and clinical capacities in the US, China, and Japan. Dr. Zifferblatt earned his MPH (Masters of Public Health) and his MBA from Berkeley. He received his MD from the UCSD School of Medicine.
Mitchell Mutz, Ph.D., is President and Chief Scientific Officer with Amplyx Pharmaceuticals. Mitchell has a Ph.D. in chemistry and began his career in drug discovery in 1997 at the Palo Alto Institute for Molecular Medicine. He later worked at Scios, Inc. before leaving to start Labcyte, Inc. Mitchell has extensive start-up experience and including successful utilization of grants to fund companies.
At Scios, Inc. in Sunnyvale, Mitchell worked on a project to discover small molecule therapeutics to treat Alzheimer’s disease. In 2000, he left Scios to start Labcyte, Inc,a company that employs acoustic beam technology to move liquid for drug screening applications. At Labcyte, Mitchell participated in raising the initial venture financing of the company, raising $5 million within his first five months of employment.
He also served as Director of Chemistry and later as Principal Scientist. Labcyte is now profitable, employs over 100 people worldwide, and its screening systems are in use at all ten of the world’s largest pharmaceutical companies. Mitchell co-founded Amplyx Pharmaceuticals with Professor Gerald Crabtree of Stanford University in 2007. Amplyx employs chemical modification to repurpose existing small molecule drugs to improve efficacy and lower toxicity. Finding it difficult to raise money from large v.c. firms for an early stage company, Amplyx instead raised money from angel investors including Life Science Angels and Tech Coast Angels, and more recently from the National Institutes of Health SBIR grant program. So far in 2012, Amplyx has been awarded four Phase I NIH SBIR grants totaling over $2.1 million in non-dilutive funding and has raised almost $3 million to date in non-dilutive funding. Amplyx operates from within the Janssen Labs incubator, housed within Janssen Pharmaceuticals in San Diego.